News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In
Important Webinar! REGISTER TODAY!

FDA’s LDT RULE: Steps to Prepare for Your FDA First Milestone Submission

WEBINAR

Thursday, November 7, 2024 at 1pm ET

First compliance milestone
arrives in just seven months!

• Assess your lab’s LDTs to keep the Winners
• Master the Roadmap to Compliance
• Calculate the Cost-Benefit of LDT Compliance

FDA U.S. Department of Health and Human Services, Food and Drug Administration

⇒⇒ SUMMARY: Laboratories face unprecedented challenges with this ruling and may need to make some difficult decisions regarding their LDT menus. Despite ongoing litigation against the new rule, the FDA expects laboratories to implement the full FDA Medical Device Quality System and be in compliance by May 6, 2025—followed by other compliance requirements for 2026 and 2027. It’s one compelling reason why this webinar is a “must attend” for you and key members of your team.

No single regulatory development will have greater impact on your lab’s clinical service menu and financial performance than the urgent need to comply with the FDA’s LDT rule. With the compliance clock ticking and the first regulatory milestone arriving in May 2025—just seven months from now—you now have the opportunity to learn the most productive steps necessary to protect the LDTs essential to patient care and your lab’s finances!

This second LDT webinar in our well-attended, ongoing series delivers to you and your team a clear path forward for achieving the twin goals of preserving your LDTs with the greatest clinical value while safeguarding the indispensable revenue generated by those same LDT.

Not only will you hear from three nationally-known experts, but you will also have the valuable opportunity to ask your most important questions and get answers specific to your lab’s unique circumstances. This webinar is organized around the three topics that you and your lab team will need to address early in your LDT compliance efforts.

Vital Topic number one addresses the absolutely critical first actions you lab must take to operationalize compliance. This deals with the first question you must answer: Which of your LDTs are highest priority and indespensable to your lab? Given the cost to bring each LDT into compliance, you’ll next learn about options for addressing your lesser priority LDTs, such as using a refer- ence lab that offers the same test. This involves a “make or buy” process as your prioritize your existing menu of LDTs for compliance

This topic introduces you to the five-part plan to operationalize and review your menu of LDTs as follows:

  • End-in-Mind Strategy
  • Financial Strategy for Today and at Exit
  • Operational Plan
  • Categorizing your LDTs into Groups: High Margin, Export Plan, and Import Plan
  • Reconciliation of Your Lab’s Financial Plan, including identifying high-risk factors and recognition of the Plan’s Upsides and Downsides.

You’ll be guided through the twists and turns of the FDA’s language about “grandfathered” tests marketed prior to May 6, 2024, and why the requirement of “no changes in technology, indications for use, or diminished performance can be landmines for unwary labs.

Vital Topic number two covers the necessary—but often overlooked—elements of the LDT rule, which has many complex elements and a five-year implementation timetable. Here is where you’ll get the necessary checklist of required action items that ensure full and timely compliance. Your expert speakers have years of experience working with the FDA on diagnostic tests and you’ll get those “insider secrets” for effective compliance that can save your team plenty of time and money while ensuring that each LDT is in full compliance with the proper documentation.

Vital Topic number three goes into detail with the the best ways to comply with the FDA’s first milestone, which arrives on May 6, 2025. This is the FDA’s Medical Device Reporting (MDR) system. It includes reporting adverse events, as well as reporting corrections and removals. The MDR system will be new to nearly all labs and differs substantially from the federal CLIA requirements labs have followed for years. Here is an invaluable guided tour that provides you with both a head start on your compliance effort, along with confidence that you will get it right the first time.

You already recognize that the FDA LDT rule has raised the stakes for every lab- oratory that offers LDTs and relies on the revenue generated by these assays. This webinar will arm you with the right right decision-making strategies and steps to use in assessing the LDTs you will keep and those you will put on the back-burner. You’ll then get the necessary action steps to be in full compliance with this complex federal LDT rule. Guarantee your place by registering today!

 

Take advantage of early bird savings by registering today!

 

 

THE DARK REPORT WEBINAR AT A GLANCE

DATE:       Thursday, November 7, 2024
TIME:        1 PM EDT; 12 Noon CDT; 10 AM PDT
PLACE:     Your smartphone, laptop, and/or computer
COST:       Individual Registration $79.95, Early Bird $69.95
COST:       Corporate Site License $249.00, Early Bird $199.00
TO REGISTER:  Click here or call 512-264-7103

 

Distinguished Presenters

Valerie Palmieri

Valerie Palmieri

CEO/Founder,
Momentum Consulting

Valerie is a seasoned executive with a proven track record in scaling and transforming high-growth biotech companies. She served as Executive Chairwoman of Aspira Women’s Health, where she spearheaded the company’s evolution from a single-product lab to a diversified technology leader. Under her guidance, Aspira expanded its product portfolio into benign pelvic mass management and endometriosis while leveraging AI and machine learning to enhance patient care and reduce costs. Recognized as a pioneer in women’s health diagnostics and a Top 10 Entrepreneur by Springboard Enterprises, Valerie brings a wealth of industry knowledge and strategic acumen to her roles. Prior positions include CEO/President of Diagnocure, Senior Vice President of Operations at Laboratory Corporation of America and DIANON Systems, Inc.

 

Dr. Kim Dickinson, MD, MBA, MPH is a Senior Pathology leader at Momentum Consulting.

Kim Dickinson, MD, MBA, MPH

Senior Pathology Leader
Momentum Consulting

Dr. Kim Dickinson is a Senior Pathology Leader at Momentum Consulting overseeing the global clinical trials and diagnostic testing, with an emphasis on anatomic, clinical and digital pathology. Advanced leadership skill set with the ability to lead and partner with teams to standardize operations across global labs while driving continuous process improvement and ensuring compliance with FDA and related regulations. Committed to advancing medicine through clinical studies/trials to support positive patient outcomes.

 

Marilyn Owens, Consultant at Momentum Consulting.

Marilyn Owens, PhD, MBA, MS

Senior Consultant
Momentum Consulting

Dr. Owens is a Senior Consultant at MOMENTUM and a seasoned healthcare executive with extensive experience in managing clinical and surgical pathology laboratories, including clinical trials. With expertise in anatomic and hematopathology, immunology, infectious disease, molecular oncology, and genetics, she has held COO and SVP roles at prominent national reference labs like Knight Diagnostic Laboratories and Caris Life Sciences.

She has managed operating budgets up to $50 million and has significant experience in CLIA/CAP laboratory operations, startup growth, and strategic planning. Dr. Owens earned her Ph.D. in Medical Microbiology and Immunology from UCLA, an MBA in Management and Strategy from Pepperdine University, and a B.S. and M.S. in Microbiology from Long Beach State University.

Brought to you by
The Dark Report
;